New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
09:15 EDTXONE, SRNE, KSS, LIQD, WMT, AVGO, VOXX, PLUG, BMY, KND, CAVM, RGSE, INCY, CLVS, AAP, GTIV, CSCOOn The Fly: Pre-market Movers
HIGHER: Cisco (CSCO), up 8% after reporting better than expected third quarter results. Avago (AVGO) is also up 0.6% and Cavium (CAVM) is up 3% following Cisco's report... Gentiva Health (GTIV), up 60% after Kindred Healthcare (KND) proposes to acquire the company for $14.00 per share in cash and stock... Advance Auto Parts (AAP), up 3.3% after raising its outlook... Clovis (CLVS), up 7.7% after reporting drug data at ASCO conference... Plug Power (PLUG), up 2.4% following upgrade at Cowen. DOWN AFTER EARNINGS: Wal-Mart (WMT), down 2.9%... Kohl's (KSS), down 3.6%... ExOne (XONE), down 15%... Real Goods Solar (RGSE), down 13.7%. ALSO LOWER: Bristol-Myers (BMY), down 4% following downgrade at BMO Capital citing last nights' ASCO abstracts discussing disappointing Nivo-Yervfoy combination data... VOXX International (VOXX), down 25% after downgraded at B. Riley following worse than expected Q4 results... Sorrento Therapeutics (SRNE), down 21% after 4.765M share secondary stock offering priced at $5.25... Incyte (INCY), down 9.7% after an abstract regarding a Phase 2 study of its pancreatic cancer drug was posted at ASCO... Liquid Holdings (LIQD), down 43.5% after its 32M share secondary priced at $1.25.
News For CSCO;CAVM;WMT;GTIV;KND;LIQD;AAP;BMY;KSS;CLVS;PLUG;SRNE;INCY;VOXX;XONE;RGSE;AVGO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
August 18, 2015
07:06 EDTWMTWal-Mart sees operating profit pressured for remainder of year
Subscribe for More Information
07:05 EDTWMTWal-Mart reports Q2 total revenue $120.2B, constant currency basis rev. $124.5B
Subscribe for More Information
07:04 EDTWMTWal-Mart reports Q2 e-commerce sales up approx. 16%
E-commerce sales globally increased approximately 16% on a constant currency basis. Gross merchandise value, or GMV, increased approximately 18% on a constant currency basis. Q2 earnings were pressured by currency fluctuations, lower Walmart U.S. margins and investments in customer experience. Consolidated operating income declined 10%. CEO Doug McMillion says, "We're pleased that the investments we've made are helping to improve our business. Even if it's not as fast as we would like, the fundamentals of serving our customers are consistently improving, and it's reflected in our comps and revenue growth. In this case, our desired changes require investments, which are pressuring earnings this year. We're confident that our strategic plan will create robust sustainable growth for shareholder returns over time."
07:03 EDTWMTWal-Mart sees Q3 EPS 93c-$1.05, consensus $1.08
Subscribe for More Information
07:03 EDTWMTWal-Mart cuts FY16 EPS view to $4.40-$4.70 from $4.70-$5.05
Consensus is $4.77.
07:02 EDTWMTWal-Mart reports Q2 EPS $1.08, consensus $1.12
Subscribe for More Information
06:12 EDTWMTWal-Mart implied volatility of 23 at upper end of index
Subscribe for More Information
August 17, 2015
15:28 EDTRGSEReal Goods Solar regains Nasdaq compliance
RGS Energy has received notification from The Nasdaq Stock Market that it has regained compliance with NASDAQ Marketplace Rules.
15:03 EDTWMTWal-Mart August 72 straddle priced for 3.6% movement into Q2
Subscribe for More Information
14:48 EDTWMTNotable companies reporting before tomorrow's open
Subscribe for More Information
14:11 EDTINCYIncyte reveals favorable early data on IDO inhibitor, says Cowen
Subscribe for More Information
14:08 EDTWMTWal-Mart August volatility increases into Q2 and outlook
Wal-Mart August call option implied volatility is at 41, September is at 23, October is at 20; compared to its 52-week range of 10 to 21 suggesting large price movement into the expected release of Q2 results on Aug 18.
12:44 EDTWMTEarnings Watch: Wal-Mart down more than 9% over last three months
Subscribe for More Information
11:18 EDTCSCOEZchip to supply chips to cloud data centers, Bloomberg says
Subscribe for More Information
10:09 EDTCSCOOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:43 EDTBMYBristol-Myers sells Ixempra to R-PHARM, terms not disclosed
R-PHARM announces the acquisition of Ixempra from Bristol-Myers Squibb. Ixempra received marketing approval from the FDA in 2007 and in 18 other markets globally. Ixempra is indicated as monotherapy or in combination with capecitabine for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine. With the acquisition, R-PHARM has launched its U.S. commercial operations, and it is now responsible for all activities surrounding Ixempra's manufacture, distribution, sales, and reimbursement. Financial terms were not disclosed.
07:39 EDTCSCOTMC to hold a conference
Subscribe for More Information
07:29 EDTWMTWal-Mart dividend and valuation provides support, says Baird
Subscribe for More Information
07:21 EDTWMTWal-Mart coverage transitioned with an Overweight at Stephens
Subscribe for More Information
06:45 EDTCSCOCisco downgraded to Equal Weight from Overweight at Morgan Stanley
Subscribe for More Information
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use